Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.
J Inorg Biochem. 2019 Jun;195:174-181. doi: 10.1016/j.jinorgbio.2019.03.022. Epub 2019 Mar 30.
In this report, we designed and synthesized a series of cobalt(II)-Schiff base complexes (CoSBC) with competent MEK1 (mitogen-activated protein kinase kinase-1) inhibitory activity. Based on our previous report, the CoSBC exhibited high binding affinity with MEK1 protein. To further explore metal complexes as MEK1 inhibitors, a series of transition metals and ligands were employed to build a library of various metal Schiff base complexes. The MEK inhibition assays revealed that only CoSBC exhibited obvious inhibitory activity, complex 2b showed the best inhibition both in BRaf (B-rapidly accelerated fibrosarcoma)/MEK1 and MEK1/ERK2 (extracellular signal-regulated kinases-2) cascading (IC is 1.988 ± 0.14 μM and 1.589 ± 0.054 μM respectively). In addition, homogeneous time-resolved fluorescence test method was used to prove that CoSBC as ATP-noncompetitive MEK1 inhibitor. MEK kinase selectivity assay indicated that CoSBC can selectively inhibit MEK1/2 kinases rather than other MAPKs (mitogen-activated protein kinases) family kinases. Moreover, the interaction mode of 2b with MEK1 protein has been demonstrated by computer aided drug design.
在本报告中,我们设计并合成了一系列具有高效 MEK1(丝裂原活化蛋白激酶激酶-1)抑制活性的钴(II)-席夫碱配合物(CoSBC)。基于我们之前的报告,CoSBC 与 MEK1 蛋白具有高结合亲和力。为了进一步探索金属配合物作为 MEK1 抑制剂,我们采用了一系列过渡金属和配体来构建各种金属席夫碱配合物库。MEK 抑制实验表明,只有 CoSBC 表现出明显的抑制活性,配合物 2b 在 BRaf(B-快速加速纤维肉瘤)/MEK1 和 MEK1/ERK2(细胞外信号调节激酶-2)级联中表现出最好的抑制作用(IC 分别为 1.988±0.14μM 和 1.589±0.054μM)。此外,均相时间分辨荧光测试方法证明 CoSBC 是一种 ATP 非竞争性 MEK1 抑制剂。MEK 激酶选择性测定表明,CoSBC 可以选择性地抑制 MEK1/2 激酶,而不是其他 MAPKs(丝裂原活化蛋白激酶)家族激酶。此外,通过计算机辅助药物设计证明了 2b 与 MEK1 蛋白的相互作用模式。